New treatment strategies in patients with advanced non-small-cell lung cancer and performance status 2

Estelamari Rodriguez, Rogerio C. Lilenbaum

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations

Abstract

Patients with performance status (PS) 2 represent approximately 30%-40% of all patients with advanced non-small-cell lung cancer (NSCLC) seen in clinical practice. Although these patients have been historically excluded from randomized clinical trials, recent studies have suggested a benefit from systemic chemotherapy. The development of biologic agents offers a new promise for the treatment of PS 2 patients as a result of the perceived improved therapeutic index of these agents. However, many of the recent advances in NSCLC have been limited to good PS patients and have not translated into an improvement in the management of the PS 2 population because the studies have excluded this patient population or have failed to demonstrate a survival benefit.

Original languageEnglish (US)
Pages (from-to)326-330
Number of pages5
JournalClinical Lung Cancer
Volume9
Issue number6
DOIs
StatePublished - Nov 2008

Keywords

  • Monoclonal antibodies
  • Platinum agents
  • Taxanes
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint

Dive into the research topics of 'New treatment strategies in patients with advanced non-small-cell lung cancer and performance status 2'. Together they form a unique fingerprint.

Cite this